Infliximabe na doença de crohn: experiência clínica de um centro terciário paulista / Infliximab in crohn's disease: clinical experience from a single tertiary center of Sao Paulo State

Introdução: Na Doença de Crohn (DC) ocorre uma reatividade anormal dos linfócitos T da mucosa intestinal e produção excessiva de citocinas pró-inflamatórias, entre as quais o fator de necrose tumoral alfa (TNF-á). O infliximabe é um anticorpo monoclonal anti-TNF-á indicado no tratamento de pacientes com DC fistulizante ou não responsiva ao tratamento convencional. Objetivos: Caracterizar as indicações clínicas do infliximabe na DC em um serviço referencial paulista, avaliandopadrões de resposta e a efetividade do tratamento através do Índice de Atividade da DC (CDAI). Pacientes e Métodos: O estudo foi observacional retrospectivo e analisou dados de 21 pacientes com DC em uso de infliximabe atendidos no Hospital de Base de RioPreto entre janeiro de 2004 e julho de 2008. Resultados: Houve predomínio de pacientes do sexo feminino (67%), com média de idade de 33 anos. As indicações mais freqüentes foram fístulas perianais (48%). Resposta clínica total à droga ocorreu em 43% dospacientes, e resposta parcial em 47%; a diferença da média do CDAI entre os grupos antes e após o tratamento foi de 244,61 pontos (p< 0,0005). Conclusões: O infliximabe induziu melhora clínica em 90% dos pacientes, acompanhada de redução da atividade dadoença na avaliação através de um índice padronizado.

Introduction: In Crohn's Disease (CD) occurs an abnormal reactivity of T lymphocytes of intestinal mucosa and anexceeding production of proinflammatory cytokines, such as the tumor necrosis factor- alpha (TNF-á). Infliximab is a monoclonal antibody against TNF-á, indicated for treatment of patients with fistulizing or refractory CD. Objectives: To characterize theclinical indications of infliximab in CD at a referral center of Sao Paulo State, assessing patterns of response and treatment effectiveness by Crohn's Disease Activity Index (CDAI). Patients and Methods: This was an observational, retrospective study; data of 21 patients with CD receiving infliximab therapy at Hospital de Base de Rio Preto between January 2004 and July 2008 were analyzed. Results: Female patients were predominant (67%) and mean age was 33 years. Perianal fistulas represented the most common indication for infliximab use (48%). Complete clinical response to drug occurred in 43% of patients, and partial response in 47%; the mean difference of CDAI between the groups, before and after infliximab treatment, was 244.61 points (p<0.0005). Conclusions: Infliximab induced clinical improvement in 90% of patients, with concomitant reduction of disease activity as measured by a standardized index.

An analysis of misdiagnosed Crohn's disease in China / 中华消化内镜杂志

Objective In order to improve the diagnostic level of Crohn's disease( CD),the relevant literatures with CD in China were reviewed and the causes of misdiagnosis about CD were analyzed. Methods Papers on CD published in medical journals from 1989 to 2003 in CMCC and VIP are collected and reviewed one by one, and then the characteristics of the misdiagnosed and missed CD were recorded and the causes of these cases were analyzed. Results From 1989 to 2003, there are 428 papers about CD, of which 261 papers are about clinical studies(60.9%); In these papers, total of 3397 CD cases were reported. In these cases there are 2357 cases missed, clinical symptoms are various and complex including abdomen pain (62.5%),diarrhea(51.5%), abdomenal lumps(16.6%) and so on. The most commonly involved sites of CD are terminal ileum (62.5%), colon (26.9%) and ileum combining with colon (38.9%). Cranulomas were identified in 61.2% of operative specimens and in 27.6% of biopsy specimens. The most common missed diagnosed diseases are intestinal tuberculosis(32. 2% ), simplex intestinal block (23.2%) and intestinal block caused by tumor(6.4%) and acute appenditis(27. 9% ). There are 389 cases misdiagnosed as CD, the most common diseases are tuberculosis(53.5%), small intestinal lymphoma(14.4%) and colonal cancer (17.0%). Conclusion Papers on CD are increased gradually during the periods from 1989 to 2003 with rather high missed or misdiagnosis. As a result, it is necessary for us to improve the cognitzability on CD and to improve the accuracy of diagnosis.